-
Nanoform successfully completes new share issue raising EUR 25 million to prepare for GMP manufacturing in the USA
-
-
Global experts in nanotechnology and drug particle engineering
Our latest videos
Press releases
-
Regulatory January 11, 2023Share subscriptions based on Nanoform Finland Plc’s stock options 3-5/2019 and 1/2020
-
Regulatory January 11, 2023Nanoform Finland Plc – Manager’s transactions – Antonio da Silva
-
Regulatory December 20, 2022Nanoform appoints Antonio da Silva as Chief of Business Operations (CBO) and member of the Management Team
Nanoform published its Interim Report January-September 2022 on November 29, 2022, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time.
a
About Nanoform
Our work enables our partners to overcome drug development challenges to rapidly progress novel drugs to market. We are driven by a passion for innovation, and constantly work to find ground-breaking solutions that enhance drug effectiveness and targeting.
Expert services
Our nanoforming services provide solutions to complex formulation challenges by increasing drug solubility and bioavailability. The advanced production of nanoparticles provides pharmacokinetic improvements, commercial opportunities and novel avenues for drug delivery.
GMP Manufacturing
Our experienced team are able to manufacture API nanoparticles created by our award-winning CESS® small-molecule nanoparticle engineering technology to GMP standards. Our GMP facility is currently able to handle OEB4 (1ug/m3) compounds.
Working together for enhanced drug development
Our nanoforming technologies and services span the full range of drug development from small-molecule nanoparticles to large-molecule biologics. We support all phases of drug development, accelerating your time to clinic for GMP manufacture while also increasing possibilities and probabilities of success in taking your product to market.
Nanoform’s platform is exciting for its broad applicability to drug development across all therapeutic areas
